1. Characterization and localization of the endothelin receptors in human end-stage heart failure
- Author
-
Francisco J. Tinahones, Arturo Fernández-Cruz, Juan José Rufilanchas, M. Rosa Bernal-Lopez, Amparo Carbonell, Ainhoa Ripodas, Ricardo Gómez-Huelgas, Raquel Fernández-Durango, and Paloma Aragoncillo
- Subjects
medicine.medical_specialty ,Ischemic cardiomyopathy ,Cardiomyopathy ,Human heart ,Bioengineering ,Biology ,medicine.disease ,Applied Microbiology and Biotechnology ,Biochemistry ,Endocrinology ,Internal medicine ,Heart failure ,cardiovascular system ,medicine ,End stage heart failure ,Receptor ,Endothelin receptor ,Endocardium - Abstract
Endothelin (ET) is a potent vasoconstrictor peptide implicated in numerous human diseases, including ischemic cardiomyopathy (ICM). ET binds to receptors ET A and ET B . Specific ET receptors were characterized in left atria of patients with end-stage heart failure due to ischemic cardiomyopathy (ICM) ( n = 9) and healthy controls ( n = 9). Saturation assays revealed a K d and B max of 28 ± 8 pM and 87 ± 22 fmol mg −1 of protein, respectively, from healthy atria and 50 ± 9 pM and 162 ± 19 fmol mg −1 of protein, respectively, from diseased atria ( p A receptors using BQ123, 55% ± 5 and 66% ± 4 in healthy and diseased atria, respectively ( p B using BQ3020 was 55% ± 14 in healthy and 59% ± 10 in diseased atria. Microautoradiography studies showed a greater number of ET receptors, predominately ET A , existed in the myocardial layer of diseased atria compared with healthy atria. The percentage of occupied area was greater in the endocardium than the epicardium in diseased atria. These results showed an increase in the ET A /ET B receptor system in the failing human heart compared with the non-failing human heart.
- Published
- 2009